Targeting of IL-2 to cytotoxic lymphocytes as an improved method of cytokine-driven immunotherapy

Eric Lazear, Reza Ghasemi, Sarah M. Hein, John Westwick, Dan Watkins, Daved H. Fremont, Alexander Sasha Krupnick

Research output: Contribution to journal › Article

1 Scopus citations

Abstract

The use of high-dose interleukin-2 (IL-2) has fallen out of favor due to severe life-threatening side effects. We have recently described a unique way of directly targeting IL-2 to cytotoxic lymphocytes using a virally encoded immune evasion protein and an IL-2 mutant that avoids off-target side effects such as activation of regulatory T cells and vascular endothelium.

Original languageEnglish
Article numbere1265721
JournalOncoImmunology
Volume6
Issue number2
DOIs
StatePublished - Feb 1 2017

Keywords

  • Cytokine
  • Interleukin-2 (IL-2)
  • NKG2D
  • cytotoxic lymphocytes
  • immunotargeting
  • immunotherapy
  • natural killer cell (NK)

Access to Document

Fingerprint Dive into the research topics of 'Targeting of IL-2 to cytotoxic lymphocytes as an improved method of cytokine-driven immunotherapy'. Together they form a unique fingerprint.

    • Cite this

    Lazear, E., Ghasemi, R., Hein, S. M., Westwick, J., Watkins, D., Fremont, D. H., & Krupnick, A. S. (2017). Targeting of IL-2 to cytotoxic lymphocytes as an improved method of cytokine-driven immunotherapy. OncoImmunology, 6(2), [e1265721]. https://doi.org/10.1080/2162402X.2016.1265721